These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1118 related articles for article (PubMed ID: 28061006)

  • 1. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
    Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
    Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
    Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup.
    Hoang LN; Kinloch MA; Leo JM; Grondin K; Lee CH; Ewanowich C; Köbel M; Cheng A; Talhouk A; McConechy M; Huntsman DG; McAlpine JN; Soslow RA; Gilks CB
    Am J Surg Pathol; 2017 Feb; 41(2):245-252. PubMed ID: 28079598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Proactive Molecular Risk Classifier for Endometrial cancer (ProMisE) with sonographic and demographic characteristics in preoperative prediction of recurrence or progression of endometrial cancer.
    Eriksson LSE; Nastic D; Lindqvist PG; Imboden S; Järnbert-Pettersson H; Carlson JW; Epstein E
    Ultrasound Obstet Gynecol; 2021 Sep; 58(3):457-468. PubMed ID: 33314410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment.
    Talhouk A; Hoang LN; McConechy MK; Nakonechny Q; Leo J; Cheng A; Leung S; Yang W; Lum A; Köbel M; Lee CH; Soslow RA; Huntsman DG; Gilks CB; McAlpine JN
    Gynecol Oncol; 2016 Oct; 143(1):46-53. PubMed ID: 27421752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
    Raffone A; Travaglino A; Gabrielli O; Micheli M; Zuccalà V; Bitonti G; Camastra C; Gargiulo V; Insabato L; Zullo F
    Arch Gynecol Obstet; 2021 Jun; 303(6):1393-1400. PubMed ID: 33754186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability.
    Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y
    PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A clinically applicable molecular-based classification for endometrial cancers.
    Talhouk A; McConechy MK; Leung S; Li-Chang HH; Kwon JS; Melnyk N; Yang W; Senz J; Boyd N; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Br J Cancer; 2015 Jul; 113(2):299-310. PubMed ID: 26172027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53, Mismatch Repair Protein, and POLE Abnormalities in Ovarian Clear Cell Carcinoma: An Outcome-based Clinicopathologic Analysis.
    Parra-Herran C; Bassiouny D; Lerner-Ellis J; Olkhov-Mitsel E; Ismiil N; Hogen L; Vicus D; Nofech-Mozes S
    Am J Surg Pathol; 2019 Dec; 43(12):1591-1599. PubMed ID: 31335355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly Classified Uterine FIGO Grade 3 Endometrioid Carcinomas Show Distinctive Clinical Outcomes But Overlapping Morphologic Features.
    Joehlin-Price A; Van Ziffle J; Hills NK; Ladwig N; Rabban JT; Garg K
    Am J Surg Pathol; 2021 Mar; 45(3):421-429. PubMed ID: 33021522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Cosgrove CM; Tritchler DL; Cohn DE; Mutch DG; Rush CM; Lankes HA; Creasman WT; Miller DS; Ramirez NC; Geller MA; Powell MA; Backes FJ; Landrum LM; Timmers C; Suarez AA; Zaino RJ; Pearl ML; DiSilvestro PA; Lele SB; Goodfellow PJ
    Gynecol Oncol; 2018 Jan; 148(1):174-180. PubMed ID: 29132872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
    Billingsley CC; Cohn DE; Mutch DG; Stephens JA; Suarez AA; Goodfellow PJ
    Cancer; 2015 Feb; 121(3):386-94. PubMed ID: 25224212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
    Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
    Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].
    Du NN; Liu Y; Ren CX; Wang YX; Du J; Yang J; Liu CR
    Zhonghua Bing Li Xue Za Zhi; 2019 Aug; 48(8):596-603. PubMed ID: 31422589
    [No Abstract]   [Full Text] [Related]  

  • 18. Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Raffone A; Travaglino A; Mascolo M; Carotenuto C; Guida M; Mollo A; Insabato L; Zullo F
    Gynecol Oncol; 2020 Apr; 157(1):252-259. PubMed ID: 31932106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups.
    Bosse T; Nout RA; McAlpine JN; McConechy MK; Britton H; Hussein YR; Gonzalez C; Ganesan R; Steele JC; Harrison BT; Oliva E; Vidal A; Matias-Guiu X; Abu-Rustum NR; Levine DA; Gilks CB; Soslow RA
    Am J Surg Pathol; 2018 May; 42(5):561-568. PubMed ID: 29505428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. POLE, MMR, and MSI Testing in Endometrial Cancer: Proceedings of the ISGyP Companion Society Session at the USCAP 2020 Annual Meeting.
    Casey L; Singh N
    Int J Gynecol Pathol; 2021 Jan; 40(1):5-16. PubMed ID: 33290350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.